151 related articles for article (PubMed ID: 36276072)
1. The
Vigliotta I; Armuzzi S; Barone M; Solli V; Pistis I; Borsi E; Taurisano B; Mazzocchetti G; Martello M; Poletti A; Sartor C; Rizzello I; Pantani L; Tacchetti P; Papayannidis C; Mancuso K; Rocchi S; Zamagni E; Curti A; Arpinati M; Cavo M; Terragna C
Front Oncol; 2022; 12():1001048. PubMed ID: 36276072
[TBL] [Abstract][Full Text] [Related]
2. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
[TBL] [Abstract][Full Text] [Related]
3. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
Tettero JM; Heidinga ME; Mocking TR; Fransen G; Kelder A; Scholten WJ; Snel AN; Ngai LL; Bachas C; van de Loosdrecht AA; Ossenkoppele GJ; de Leeuw DC; Cloos J; Janssen JJWM
Leukemia; 2024 Mar; 38(3):630-639. PubMed ID: 38272991
[TBL] [Abstract][Full Text] [Related]
4. Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma.
Jiang D; Zhang Y; Tan S; Liu J; Li X; Zhang C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230860
[TBL] [Abstract][Full Text] [Related]
5. B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
Mendonça de Pontes R; Flores-Montero J; Sanoja-Flores L; Puig N; Pessoa de Magalhães RJ; Corral-Mateos A; Salgado AB; García-Sánchez O; Pérez-Morán J; Mateos MV; Burgos L; Paiva B; Te Marvelde J; van der Velden VHJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; Durie B; van Dongen JJM; Maiolino A; Sobral da Costa E; Orfao A
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916787
[TBL] [Abstract][Full Text] [Related]
6. Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
Puig N; Flores-Montero J; Burgos L; Cedena MT; Cordón L; Pérez JJ; Sanoja-Flores L; Manrique I; Rodríguez-Otero P; Rosiñol L; Martínez-López J; Mateos MV; Lahuerta JJ; Bladé J; San Miguel JF; Orfao A; Paiva B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638406
[TBL] [Abstract][Full Text] [Related]
7. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index.
Óskarsson JÞ; Rögnvaldsson S; Thorsteinsdottir S; Aspelund T; Gunnarsson SB; Hákonardóttir GK; Sigurðardóttir GÁ; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Sigurðsson JK; Eyþórsson E; Jónsson Á; Viðarsson B; Önundarson PT; Agnarsson BA; Pálmason R; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Harding S; Flores-Montero J; Orfao A; Durie BGM; Love TJ; Kristinsson SY
Blood Cancer J; 2023 Dec; 13(1):177. PubMed ID: 38040702
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
9. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
10. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly L; Sundaram V; Chen C; Yurkiewicz I; Kuo E; Burnash S; Spiegel JY; Arai S; Frank MJ; Johnston LJ; Lowsky R; Meyer EH; Negrin RS; Rezvani AR; Sidana S; Shiraz P; Shizuru JA; Weng WK; Liedtke M; Vempaty HT; Miklos DB
Blood Adv; 2021 Aug; 5(16):3147-3151. PubMed ID: 34424318
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
12. Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry.
Li W; Morgan R; Nieder R; Truong S; Habeebu SSM; Ahmed AA
Cytometry B Clin Cytom; 2021 Sep; 100(5):590-601. PubMed ID: 33197125
[TBL] [Abstract][Full Text] [Related]
13. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Thompson PA; Srivastava J; Peterson C; Strati P; Jorgensen JL; Hether T; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Wierda WG
Blood; 2019 Nov; 134(22):1951-1959. PubMed ID: 31537528
[TBL] [Abstract][Full Text] [Related]
15. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment.
Kriegsmann K; Hundemer M; Hofmeister-Mielke N; Reichert P; Manta CP; Awwad MHS; Sauer S; Bertsch U; Besemer B; Fenk R; Hänel M; Munder M; Weisel KC; Blau IW; Neubauer A; Müller-Tidow C; Raab MS; Goldschmidt H; Huhn S; For The German-Speaking Myeloma Multicenter Group Gmmg
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824635
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
18. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease.
Keegan A; Charest K; Schmidt R; Briggs D; Deangelo DJ; Li B; Morgan EA; Pozdnyakova O
J Clin Pathol; 2018 Jul; 71(7):653-658. PubMed ID: 29588374
[TBL] [Abstract][Full Text] [Related]
20. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
